<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086761</url>
  </required_header>
  <id_info>
    <org_study_id>MP0112-CP01</org_study_id>
    <nct_id>NCT01086761</nct_id>
  </id_info>
  <brief_title>Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration</brief_title>
  <official_title>A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Molecular Partners AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of MP0112 (a novel,
      potentially long acting VEGF inhibitor) in patients with wet Age Related Macular
      Degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to a company decision following completion of Part A.
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerated Dose (MTD) Following a Single Injection</measure>
    <time_frame>16 weeks</time_frame>
    <description>MTD was defined as one dose level below the lower of the dose level in which a severe (sight-threatening) drug-related Adverse Event occurred or the dose level at which more than 2 patients experienced a moderate ocular (eye) drug-related toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Stable or Improved Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>BCVA was measured using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye at Baseline and Week 4. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the letters read correctly on the eye chart the better the vision. Stable or Improved BCVA was defined as a loss of &lt;15 letters read correctly compared to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Area Retinal Thickness</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at Baseline and Week 4. A negative change from Baseline indicated improvement (less retinal thickness). A positive change from Baseline indicated worsening (definite retinal thickening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Leakage as Measured by Fluorescein Angiography</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA was performed on the dilated study eye 10 minutes after fluorescein application at Baseline and Week 4. A lower number indicated a smaller area of leakage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of Lesion as Measured by Fluorescein Angiography</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA was performed on the dilated study eye after fluorescein application at Baseline and Week 4. A lower number indicated a smaller lesion area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of MP0112 at Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Blood samples were collected for MP0112 levels on Day 3. The serum samples (liquid portion of the blood after cells and clotting factors were removed) were sent to a laboratory and were analyzed for MP0112 levels using an enzyme-linked immunosorbent assay. Maximum concentration at Day 3 was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Binding Anti-MP0112 Antibodies</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood samples were collected Pre-treatment (Baseline) and Weeks 4, 8 and 12. Samples were analyzed for Anti-MP0112 antibodies using an enzyme-linked immunosorbent assay.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Wet Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>MP0112 (0.04 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP0112 (0.15 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP0112 (0.4 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP0112 (1.0 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP0112 (2.0 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP0112 (3.6 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 3.6 mg intravitreal injection of MP0112 in the study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MP0112</intervention_name>
    <description>Single intravitreal injection of MP0112 in the study eye.</description>
    <arm_group_label>MP0112 (0.04 mg)</arm_group_label>
    <arm_group_label>MP0112 (0.15 mg)</arm_group_label>
    <arm_group_label>MP0112 (0.4 mg)</arm_group_label>
    <arm_group_label>MP0112 (1.0 mg)</arm_group_label>
    <arm_group_label>MP0112 (2.0 mg)</arm_group_label>
    <arm_group_label>MP0112 (3.6 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs and angiographic evidence of active primary progressive subfoveal
             choroidal neovascularisation (CNV), including juxtafoveal lesions that affect the
             fovea on FA in the study eye that is at least 50% of the total lesion area

          -  ETDRS best-corrected visual acuity of: 20/40 to 20/320 in the study eye at 4 meters

          -  Male or female age &gt; 50 years

          -  Written informed consent prior to any study procedures

          -  Willing, committed, and able to return for ALL clinic visits and complete all
             study-related procedures.

        Exclusion Criteria:

          -  Prior treatment with anti-VEGF therapy in the study eye, including bevacizumab,
             ranibizumab, or pegaptanib, as well as photodynamic therapy with verteporfin

          -  Any prior or concomitant therapy with another investigational agent to treat
             neovascular AMD in the study eye, except dietary supplements or vitamins

          -  Subfoveal thermal laser therapy, external-beam radiation therapy, or transpupillary
             thermotherapy in the study eye

          -  Extrafoveal laser coagulation treatment within 12 weeks prior to Baseline in the study
             eye

          -  Total lesion size &gt; 20mm2 (including blood, scars and neovascularization) as assessed
             by FA in the study eye

          -  Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the
             blood is under the fovea and is 2.54mm2 or more in size in the study eye

          -  Scar or fibrosis, making up &gt; 50% of total lesion in the study eye

          -  Scar, fibrosis, or atrophy involving the center of the fovea

          -  Presence of retinal pigment epithelial tears or rips

          -  History of any vitreous hemorrhage within 4 weeks prior to Visit 1 or current
             hemorrhage in the study eye

          -  Presence of other causes of CNV, including pathologic myopia (spherical equivalent of
             -8 diopters or more negative, or axial length of 25 mm or more), ocular histoplasmosis
             syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study
             eye

          -  History or clinical evidence of diabetic retinopathy, diabetic macular oedema or any
             other vascular disease affecting the retina, other than AMD, in either eye

          -  Prior vitrectomy in the study eye

          -  History of retinal detachment or treatment or surgery for retinal detachment in the
             study eye

          -  Ocular surgery (including cataract removal) in the study eye within 3 months of
             enrolment

          -  Active intraocular inflammation (grade trace or above) in the study eye

          -  History of allergy to any components of the study drug or diagnostic devices, such as
             fluorescein

          -  Advanced glaucoma or intraocular pressure above 22 mmHg in the study eye despite
             treatment

          -  Inability to obtain fundus photographs or fluorescein angiogram of sufficient quality
             to be analyzed and graded by the central reading center

          -  History of idiopathic or autoimmune-associated uveitis in either eye

          -  Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

          -  Aphakia or absence of the posterior capsule in the study eye

          -  Presence of a non-healing wound, ulcer, fracture or any other medical condition
             associated with bleeding

          -  Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination
             half-lives of enrolment

          -  Premenopausal women

          -  Any disorder or condition that contraindicates the use of an investigational drug

          -  Participation in another investigational drug study within 3 months of enrolment

          -  Uncontrolled hypertension

          -  Previous stroke within 12 months of study entry

          -  Systemic treatment with any anti-VEGF drug

          -  Current treatment for active systemic infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fakultni Nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <state>Czech</state>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <state>Czech</state>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ustrendi Vojenska Nemocnice</name>
      <address>
        <city>Praha</city>
        <state>Czech</state>
        <zip>16902</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Intercommunual de Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rabelais</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paradis-Monticelli</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <results_first_submitted>April 14, 2014</results_first_submitted>
  <results_first_submitted_qc>April 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2014</results_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MP0112 (0.04 mg)</title>
          <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="P2">
          <title>MP0112 (0.15 mg)</title>
          <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="P3">
          <title>MP0112 (0.4 mg)</title>
          <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="P4">
          <title>MP0112 (1.0 mg)</title>
          <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="P5">
          <title>MP0112 (2.0 mg)</title>
          <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="P6">
          <title>MP0112 (3.6 mg)</title>
          <description>Single 3.6 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MP0112 (0.04 mg)</title>
          <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="B2">
          <title>MP0112 (0.15 mg)</title>
          <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="B3">
          <title>MP0112 (0.4 mg)</title>
          <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="B4">
          <title>MP0112 (1.0 mg)</title>
          <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="B5">
          <title>MP0112 (2.0 mg)</title>
          <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.2" spread="6.3"/>
                    <measurement group_id="B2" value="78.6" spread="3.2"/>
                    <measurement group_id="B3" value="77.5" spread="6.0"/>
                    <measurement group_id="B4" value="79.0" spread="3.0"/>
                    <measurement group_id="B5" value="77.8" spread="9.4"/>
                    <measurement group_id="B6" value="78.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Tolerated Dose (MTD) Following a Single Injection</title>
        <description>MTD was defined as one dose level below the lower of the dose level in which a severe (sight-threatening) drug-related Adverse Event occurred or the dose level at which more than 2 patients experienced a moderate ocular (eye) drug-related toxicity.</description>
        <time_frame>16 weeks</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>MP0112</title>
            <description>Single intravitreal injection of MP0112 in the study eye of one of the following doses: 0.04 mg, 0.15 mg, 0.4 mg, 1.0 mg or 2.0 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Tolerated Dose (MTD) Following a Single Injection</title>
          <description>MTD was defined as one dose level below the lower of the dose level in which a severe (sight-threatening) drug-related Adverse Event occurred or the dose level at which more than 2 patients experienced a moderate ocular (eye) drug-related toxicity.</description>
          <population>All treated participants.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Stable or Improved Best Corrected Visual Acuity (BCVA)</title>
        <description>BCVA was measured using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye at Baseline and Week 4. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the letters read correctly on the eye chart the better the vision. Stable or Improved BCVA was defined as a loss of &lt;15 letters read correctly compared to Baseline.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>MP0112 (0.04 mg)</title>
            <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O2">
            <title>MP0112 (0.15 mg)</title>
            <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O3">
            <title>MP0112 (0.4 mg)</title>
            <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O4">
            <title>MP0112 (1.0 mg)</title>
            <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O5">
            <title>MP0112 (2.0 mg)</title>
            <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stable or Improved Best Corrected Visual Acuity (BCVA)</title>
          <description>BCVA was measured using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye at Baseline and Week 4. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the letters read correctly on the eye chart the better the vision. Stable or Improved BCVA was defined as a loss of &lt;15 letters read correctly compared to Baseline.</description>
          <population>All treated participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Area Retinal Thickness</title>
        <description>Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at Baseline and Week 4. A negative change from Baseline indicated improvement (less retinal thickness). A positive change from Baseline indicated worsening (definite retinal thickening).</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>MP0112 (0.04 mg)</title>
            <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O2">
            <title>MP0112 (0.15 mg)</title>
            <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O3">
            <title>MP0112 (0.4 mg)</title>
            <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O4">
            <title>MP0112 (1.0 mg)</title>
            <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O5">
            <title>MP0112 (2.0 mg)</title>
            <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Area Retinal Thickness</title>
          <description>Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed in the study eye after pupil dilation at Baseline and Week 4. A negative change from Baseline indicated improvement (less retinal thickness). A positive change from Baseline indicated worsening (definite retinal thickening).</description>
          <population>All treated participants.</population>
          <units>Î¼m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353.0" spread="79.3"/>
                    <measurement group_id="O2" value="338.0" spread="69.7"/>
                    <measurement group_id="O3" value="367.2" spread="213.5"/>
                    <measurement group_id="O4" value="333.3" spread="79.4"/>
                    <measurement group_id="O5" value="375.3" spread="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="118.2"/>
                    <measurement group_id="O2" value="10.1" spread="102.8"/>
                    <measurement group_id="O3" value="-39.8" spread="72.4"/>
                    <measurement group_id="O4" value="-95.0" spread="91.2"/>
                    <measurement group_id="O5" value="-99.0" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of Leakage as Measured by Fluorescein Angiography</title>
        <description>Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA was performed on the dilated study eye 10 minutes after fluorescein application at Baseline and Week 4. A lower number indicated a smaller area of leakage.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>MP0112 (0.04 mg)</title>
            <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O2">
            <title>MP0112 (0.15 mg)</title>
            <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O3">
            <title>MP0112 (0.4 mg)</title>
            <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O4">
            <title>MP0112 (1.0 mg)</title>
            <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O5">
            <title>MP0112 (2.0 mg)</title>
            <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Area of Leakage as Measured by Fluorescein Angiography</title>
          <description>Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA was performed on the dilated study eye 10 minutes after fluorescein application at Baseline and Week 4. A lower number indicated a smaller area of leakage.</description>
          <population>All treated participants.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="4.0"/>
                    <measurement group_id="O2" value="9.5" spread="3.0"/>
                    <measurement group_id="O3" value="12.8" spread="5.9"/>
                    <measurement group_id="O4" value="8.4" spread="4.0"/>
                    <measurement group_id="O5" value="10.2" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=9,7,6,6,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="4.9"/>
                    <measurement group_id="O2" value="2.6" spread="3.5"/>
                    <measurement group_id="O3" value="2.4" spread="3.8"/>
                    <measurement group_id="O4" value="1.0" spread="2.4"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of Lesion as Measured by Fluorescein Angiography</title>
        <description>Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA was performed on the dilated study eye after fluorescein application at Baseline and Week 4. A lower number indicated a smaller lesion area.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>All treated participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MP0112 (0.04 mg)</title>
            <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O2">
            <title>MP0112 (0.15 mg)</title>
            <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O3">
            <title>MP0112 (0.4 mg)</title>
            <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O4">
            <title>MP0112 (1.0 mg)</title>
            <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O5">
            <title>MP0112 (2.0 mg)</title>
            <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Area of Lesion as Measured by Fluorescein Angiography</title>
          <description>Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA was performed on the dilated study eye after fluorescein application at Baseline and Week 4. A lower number indicated a smaller lesion area.</description>
          <population>All treated participants with data available for analysis.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="3.9"/>
                    <measurement group_id="O2" value="8.0" spread="3.6"/>
                    <measurement group_id="O3" value="12.1" spread="6.9"/>
                    <measurement group_id="O4" value="9.5" spread="4.4"/>
                    <measurement group_id="O5" value="10.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=9,6,6,6,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="4.8"/>
                    <measurement group_id="O2" value="6.2" spread="3.9"/>
                    <measurement group_id="O3" value="6.8" spread="4.1"/>
                    <measurement group_id="O4" value="7.3" spread="4.6"/>
                    <measurement group_id="O5" value="11.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax) of MP0112 at Day 3</title>
        <description>Blood samples were collected for MP0112 levels on Day 3. The serum samples (liquid portion of the blood after cells and clotting factors were removed) were sent to a laboratory and were analyzed for MP0112 levels using an enzyme-linked immunosorbent assay. Maximum concentration at Day 3 was calculated.</description>
        <time_frame>Day 3</time_frame>
        <population>Pharmacokinetic (PK) Population included all treated participants with PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>MP0112 (0.04 mg)</title>
            <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O2">
            <title>MP0112 (0.15 mg)</title>
            <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O3">
            <title>MP0112 (0.4 mg)</title>
            <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O4">
            <title>MP0112 (1.0 mg)</title>
            <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O5">
            <title>MP0112 (2.0 mg)</title>
            <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax) of MP0112 at Day 3</title>
          <description>Blood samples were collected for MP0112 levels on Day 3. The serum samples (liquid portion of the blood after cells and clotting factors were removed) were sent to a laboratory and were analyzed for MP0112 levels using an enzyme-linked immunosorbent assay. Maximum concentration at Day 3 was calculated.</description>
          <population>Pharmacokinetic (PK) Population included all treated participants with PK data.</population>
          <units>Nanomolar (nM)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Result is below the lower limit of quantitation of the laboratory test: &lt;0.3 nM.</measurement>
                    <measurement group_id="O2" value="NA">Result is below the lower limit of quantitation of the laboratory test: &lt;0.3 nM.</measurement>
                    <measurement group_id="O3" value="NA">Result is below the lower limit of quantitation of the laboratory test: &lt;0.3 nM.</measurement>
                    <measurement group_id="O4" value="0.5"/>
                    <measurement group_id="O5" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Binding Anti-MP0112 Antibodies</title>
        <description>Blood samples were collected Pre-treatment (Baseline) and Weeks 4, 8 and 12. Samples were analyzed for Anti-MP0112 antibodies using an enzyme-linked immunosorbent assay.</description>
        <time_frame>12 weeks</time_frame>
        <population>Safety Population included all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>MP0112 (0.04 mg)</title>
            <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O2">
            <title>MP0112 (0.15 mg)</title>
            <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O3">
            <title>MP0112 (0.4 mg)</title>
            <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O4">
            <title>MP0112 (1.0 mg)</title>
            <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
          <group group_id="O5">
            <title>MP0112 (2.0 mg)</title>
            <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Binding Anti-MP0112 Antibodies</title>
          <description>Blood samples were collected Pre-treatment (Baseline) and Weeks 4, 8 and 12. Samples were analyzed for Anti-MP0112 antibodies using an enzyme-linked immunosorbent assay.</description>
          <population>Safety Population included all treated participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MP0112 (0.04 mg)</title>
          <description>Single 0.04 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="E2">
          <title>MP0112 (0.15 mg)</title>
          <description>Single 0.15 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="E3">
          <title>MP0112 (0.4 mg)</title>
          <description>Single 0.4 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="E4">
          <title>MP0112 (1.0 mg)</title>
          <description>Single 1.0 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
        <group group_id="E5">
          <title>MP0112 (2.0 mg)</title>
          <description>Single 2.0 mg intravitreal injection of MP0112 in the study eye.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anterior chamber inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anterior chamber cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Corneal epithelium defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Macular cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ocular toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pseudoendophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Retinal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Subretinal fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vitreal cells</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vitreous opacities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vitritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Intraocular pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

